Bicara Therapeutics Inc. BCAX
10.18 USD +0.20 (+2.00%)
At closeNov 10, 2026, 5:13 PM EST
10.17 -0.01 -0.10%
After hours · Nov 10, 5:13 PM ET
9.45 Day range 10.33
7.93 52-week range 30.40
- YTD
- -39.51%
- 1 year
- -26.92%
News
benzinga.com Morgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30 Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and lowers the price target from $41 to $30.
benzinga.com Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43 Stifel analyst Stephen Willey maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $43.
benzinga.com BTIG Maintains Buy on Bicara Therapeutics, Lowers Price Target to $37 BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $39 to $37.
seekingalpha.com Bicara Therapeutics Inc. (BCAX) Q3 2026 Earnings Call Transcript Bicara Therapeutics Inc. (BCAX) Q3 2026 Earnings Call Transcript
marketbeat.com What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call Bicara Therapeutics NASDAQ: BCAX said its pivotal study of FICERA in a form of advanced head and neck cancer has reached sufficient enrollment to support a planned top-line interim analysis in…
benzinga.com Bicara Therapeutics Q3 2026 Earnings Call Transcript Bicara Therapeutics (NASDAQ:BCAX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com Bicara Therapeutics Q3 EPS $(1.04) Misses $(0.81) Estimate Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.81) by 28.4 percent. This is a 55.22 percent decrease over losses…
globenewswire.com Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027 Enrolling FORTIFI-FLEX alternate dosing study;…
globenewswire.com Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
benzinga.com Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.
globenewswire.com Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
benzinga.com Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8 Goldman Sachs analyst Richard Law downgrades Bicara Therapeutics (NASDAQ:BCAX) from Neutral to Sell and lowers the price target from $20 to $8.- benzinga.com Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24 Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and lowers the price target from $33 to $24.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
defenseworld.net Bicara Therapeutics (NASDAQ:BCAX) Given Buy Rating at BTIG Research Bicara Therapeutics (NASDAQ: BCAX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at BTIG Research in a research report issued on Monday, Benzinga reports. They…
benzinga.com BTIG Reiterates Buy on Bicara Therapeutics, Maintains $39 Price Target BTIG analyst Jeet Mukherjee reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Buy and maintains $39 price target.
globenewswire.com Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
globenewswire.com Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
benzinga.com BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35 BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.
globenewswire.com Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
defenseworld.net Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX Dimensional Fund Advisors LP grew its holdings in Bicara Therapeutics Inc. (NASDAQ: BCAX) by 166.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and…- benzinga.com Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20 Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
benzinga.com Wedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33 Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.- benzinga.com Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $39 Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $37 to $39.
seekingalpha.com Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but…- benzinga.com Mizuho Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20 Mizuho analyst Joseph Catanzaro maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
benzinga.com Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.
benzinga.com Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings- benzinga.com Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $23 Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $16 to $23.
- benzinga.com BTIG Maintains Buy on Bicara Therapeutics, Raises Price Target to $39 BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and raises the price target from $28 to $39.
seekingalpha.com Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
marketbeat.com Bicara Therapeutics Q2 Earnings Call Highlights Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of…- benzinga.com Bicara Therapeutics Q2 EPS $(0.82) Beats $(0.84) Estimate Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 64 percent decrease over losses of…
globenewswire.com Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock…
globenewswire.com Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
globenewswire.com Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients…
fool.com What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors? CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of…
seekingalpha.com Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
marketbeat.com Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer Bicara Therapeutics NASDAQ: BCAX said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by…
benzinga.com Bicara Therapeutics' Ficerafusp Alfa Plus Pembrolizumab Shows 31% Estimated 3-Year Overall Survival And Durable Responses In First-Line HPV-Negative Head And Neck Cancer Phase 1b Study At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a
benzinga.com Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $18 Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $16 to $18.- benzinga.com Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $37 Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $36 to $37.
- benzinga.com Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42 Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $42.
- benzinga.com Bicara Therapeutics Q1 EPS $(0.93) Misses $(0.68) Estimate Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.68) by 36.76 percent. This is a 36.76 percent decrease over losses…
benzinga.com Earnings Scheduled For May 11, 2026 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $16 Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $14 to $16.
- benzinga.com Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bicara Therapeutics, Raises Price Target to $16 Wells Fargo analyst Eva Fortea Verdejo maintains Bicara Therapeutics (NASDAQ:BCAX) with a Equal-Weight and raises the price target from $11 to $16.